Physician profile
Aaron Mestemaker
NPI 1407631104
$2,223.91
in general payments reported to CMS, 2019-2025
26 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $452 · 2024: $662 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $340.78 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $192.03 | 2024-2025 | Lifevest |
| Amgen INC. | $177.75 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.15 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $156.83 | 2023-2025 | |
| Novo Nordisk INC | $152.55 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $151.59 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $95.36 | 2023-2025 | Verquvo |
| Boston Scientific Corporation | $88.61 | 2023-2025 | Watchman Flx, Watchman |
| Lexicon Pharmaceuticals, INC. | $88.49 | 2023-2024 | Inpefa |
| Impulse Dynamics (USA) INC. | $62.37 | 2023-2025 | Optimizer, Optimizer |
| Pfizer INC. | $61.62 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $57.07 | 2024-2025 | Onpattro |
| Abiomed | $55.94 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $52.53 | 2023-2025 | Farxiga, Brilinta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $47.74 | 2025 | |
| Scpharmaceuticals INC. | $45.61 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $40.08 | 2024-2025 | Uptravi, Opsumit |
| Lilly USA, LLC | $39.11 | 2025 | Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $26.14 | 2024 | Arcalyst |
| Xeris Pharmaceuticals, INC. | $24.71 | 2025 | Keveyis |
| Medtronic, INC. | $23.88 | 2025 | Concertotm |
| Corcept Therapeutics | $22.17 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $16.82 | 2023 | Nexletol |
| Bridgebio Pharma, INC. | $14.87 | 2025 | Attruby |
| Daiichi Sankyo INC. | $14.11 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Mestemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.